What is AstraZeneca?
AstraZeneca is a global, science-led biopharmaceutical business focused on the discovery, development, and commercialization of prescription medicines. The company's core therapeutic areas include Oncology and BioPharmaceuticals, encompassing treatments for Cardiovascular, Renal & Metabolism, and Respiratory & Immunology conditions. Headquartered in the United Kingdom, AstraZeneca is committed to pushing the boundaries of science to deliver life-changing medicines.
How much funding has AstraZeneca raised?
AstraZeneca has raised a total of $4.7B across 3 funding rounds:
Other Financing Round
$1B
Other Financing Round
$168M
Unspecified
$3.5B
Other Financing Round (2020): $1B with participation from Barda Ltd
Other Financing Round (2021): $168M led by Vaccitech Limited, M&G plc, Oxford Sciences Enterprises, and Gilead Sciences Inc
Unspecified (2024): $3.5B, investors not publicly disclosed
Key Investors in AstraZeneca
Barda Ltd
Barda Ltd is an investor participating in the company's financing rounds.
Oxford Sciences Enterprises
Oxford Science Enterprises is an independent investment company focused on founding, funding, and building transformational businesses, often in partnership with leading research institutions like the University of Oxford.
Vaccitech Limited
Vaccitech Limited is an investor that has provided backing to AstraZeneca.
What's next for AstraZeneca?
The substantial enterprise-level funding indicates AstraZeneca is poised for significant expansion and continued innovation. This strategic capital infusion will likely accelerate research and development pipelines, potentially leading to new drug discoveries and the scaling of existing commercial operations. The company's focus on critical therapeutic areas suggests a strategic direction aimed at addressing major global health challenges and solidifying its market leadership.
See full AstraZeneca company page
